Endocrinology

Mounjaro: Is a dual agonist the new standard for CV protection?

Mounjaro (tirzepatide) received approval to reduce major adverse cardiovascular events in adults with type 2 diabetes, adding a dual GIP/GLP-1 agonist to the CV risk reduction arsenal.

Gender-affirming hormones: Bone density gains for some, losses for others?

Gender-affirming hormone therapy significantly increased lumbar spine bone mineral density in transgender teens assigned male at birth.

GLP-1s: Weight down, but steps down too? The paradox clinicians face

GLP-1 receptor agonists drive significant weight loss, but some patients experience a concurrent reduction in physical activity.

GLP-1s and hair loss: Is it the drug or the diet?

Rapid weight loss from GLP-1 receptor agonists can trigger telogen effluvium, a temporary hair shedding condition. Clinicians should counsel patients on this potential side effect and its management.

Traditional Chinese Medicines Plus Metformin: An A1c Advantage?

Combining Traditional Chinese Medicines with metformin may offer additional A1c reductions for patients with type 2 diabetes.

Why 12-month biochemical response is the critical pivot in endocrine disease

Assessing biochemical response at 12 months is a key decision point across several endocrine conditions, setting the long-term prognostic trajectory for patients.

Active Surveillance for Papillary Thyroid Microcarcinoma: A Decade of Data

Active surveillance for low-risk papillary thyroid microcarcinoma shows comparable long-term oncological outcomes to immediate surgery, with significantly fewer interventions.

Biochemical Response at 12 Months: The Prognostic Crossroads

Assessing biochemical response at 12 months is a critical decision point in chronic disease management, setting long-term prognosis and guiding therapeutic adjustments.

Denosumab: A New Role in Joint Protection for Osteoporosis?

Denosumab, a standard osteoporosis treatment, may offer additional benefits in protecting joint integrity in adults with osteoporosis.